KLOW Blend
Also referenced as: KLOW 80 mg, KPV + GHK-Cu + BPC-157 + TB-500 blend
A four-component research blend adding KPV to the GHK-Cu, BPC-157 and TB-500 combination, typically supplied as an 80 mg vial.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Not an approved medicine in any form. BPC-157 is prohibited in sport. Sold as research-use-only material.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- September 14, 2026
Overview
KLOW is a vendor-coined name for a blend of KPV, GHK-Cu, BPC-157 and TB-500. The name has no regulatory or pharmaceutical standing.
KPV is the C-terminal tripeptide of alpha-MSH, studied in laboratory models of intestinal and skin inflammation. Its inclusion is the stated difference from GLOW blends.
Component ratios vary by supplier, so an 80 mg total does not define the formulation. Confirm the split against a certificate of analysis before any research use.
Why It's Being Studied
- Anti-inflammatory signalling from the alpha-MSH fragment KPV in gut and skin models.
- Collagen and matrix regulation by copper peptides.
- Angiogenesis and cell migration in wound models.
- Combined inflammation and repair claims, which are untested as a combination.
Mechanism of Action
One component is studied for calming inflammation, the others for tissue and skin repair in laboratory models. The blend combines them in a single vial.
KPV (Lys-Pro-Val) is reported to inhibit NF-κB and MAPK inflammatory signalling in intestinal epithelial and immune cell models, with peptide transporter-mediated uptake. GHK-Cu modulates matrix metalloproteinase and collagen expression in fibroblast culture. BPC-157 shows VEGF-A/eNOS-linked angiogenic effects in rodents, and TB-500 sequesters actin monomers to promote cell migration. No combined pharmacology has been published.
Research Areas & Routes Studied
- Intestinal inflammation
- Skin inflammation
- Wound healing
- Soft-tissue repair
- Subcutaneous injection (research)
- Oral and topical KPV in laboratory studies
Evidence Summary
All four components rest on laboratory or animal research for the purposes claimed, and the four-way combination has no human data at all.
Human clinical evidence
- No controlled human trials of the blend or of KPV for these uses have been identified.
In-vitro studies
- Epithelial and immune cell studies report reduced inflammatory signalling with KPV.
- Fibroblast studies report matrix and collagen gene changes with GHK-Cu.
Animal studies
- Colitis models report reduced inflammation with KPV; injury models underpin the repair claims for the other components.
Anecdotal / community information
- Gut-comfort, skin and recovery reports circulate in communities and are uncontrolled.
Reported Adverse Events in Research
- No systematic human safety data exist for any component by injection, or for the blend.
- Injection-site reactions and irritation are commonly reported with copper peptides.
- Contamination and identity risk applies to research-use-only material.
- Theoretical concern about angiogenic and immune-modulating activity in undiagnosed disease.
Limitations of Current Evidence
- Four components in one vial make attribution of any effect impossible.
- Ratios are not standardised across suppliers.
- Animal colitis and wound models translate poorly to human outcomes.
Why It Is Used
- Skin & Hair
Skin, Hair and Wound Healing
The KLOW and GLOW stacks are the most-discussed cosmetic peptide combinations. Here is what each ingredient actually has behind it.
Read the case study
Research References
- Animal study
KPV tripeptide and intestinal inflammation in experimental colitis
- In-vitro study
GHK-Cu peptide in skin regeneration
- Narrative review
BPC-157 and thymosin beta-4 in tissue repair